

Vitamin B6 regulates mRNA expression of peroxisome proliferator-activated receptor- γ target genes

NORIYUKI YANAKA, MAYUMI KANDA, KEIGO TOYA, HARUNA SUEHIRO and NORIHISA KATO

Department of Bioresource Science and Technology, Graduate School of Biosphere Science,
Hiroshima University, Higashi-Hiroshima 739-8528, Japan

Received January 19, 2011; Accepted March 16, 2011

DOI: 10.3892/etm.2011.238

Abstract. We previously demonstrated that vitamin B6 suppresses tumorigenesis in the colon of mice and exerts an anti-inflammatory effect through the inhibition of NF- κ B activation. As these effects resemble the pharmacological properties of thiazolidinedione (TZD), a synthetic peroxisome proliferator-activated receptor- γ (PPAR γ) ligand, this study was designed to examine the effect of vitamin B6 on the activation of PPAR γ and adipogenesis in 3T3-L1 adipocyte cells. Pyridoxal 5'-phosphate (PLP), one of the vitamin B6 derivatives, was shown to promote adipogenesis in the 3T3-L1 adipocytes. In addition, PLP specifically induced mRNA expression of PPAR γ target genes in the 3T3-L1 adipocytes and enhanced the lipid accumulation and adipocyte fatty acid-binding protein (aP2) mRNA expression in NIH3T3 cells stably expressing PPAR γ . Furthermore, the administration of vitamin B6 increased the expression of aP2 mRNA in mouse adipose tissues. Collectively, these observations suggest a novel function of vitamin B6 as an activator for PPAR γ , which may contribute to the anti-tumor and anti-inflammatory effects of vitamin B6.

Introduction

Vitamin B6 is well known as a water-soluble vitamin essential for normal growth, development and metabolism. Natural vitamin B6 consists of six interconvertible compounds: pyridoxine, pyridoxal, pyridoxamine and their phosphorylated forms, pyridoxine 5'-phosphate, pyridoxal 5'-phosphate (PLP)

and pyridoxamine 5'-phosphate. In particular, PLP is a biologically active form of vitamin B6 and functions as a cofactor for numerous enzymes involved in amino acid and cellular metabolisms (1). Vitamin B6 has been classically classified as a coenzyme; however, recent reports have prompted us to consider other physiological functions for vitamin B6. Vitamin B6 has been reported to play an important protective role against several types of diseases (2-4). We previously demonstrated a preventive effect of dietary vitamin B6 in moderate dosage against tumorigenesis in the colon of mice which were administered azoxymethane (AOM) (5). Further studies have demonstrated that the anti-tumorigenesis effect of vitamin B6 in the colon of AOM-injected mice may be mediated, in part, via the suppression of cell hyperproliferation, inducible nitric oxide synthase (iNOS) expression and oxidative stress (5,6). Matsubara *et al* found an anti-angiogenic effect of vitamin B6 in an *ex vivo* serum-free matrix culture using rat aortic ring models (7). Furthermore, our recent study revealed an anti-inflammatory effect of vitamin B6, showing that treatment with vitamin B6 inhibits lipopolysaccharide (LPS)-induced iNOS and cyclooxygenase-2 (COX2) expression in RAW 264.7 cells through suppression of NF- κ B activation, the pro-inflammatory transcription factor (8). In addition to this *in vitro* experiment, dietary vitamin B6 inhibited nitric oxide (NO) production in response to LPS administration *in vivo* (8). Since angiogenesis and inflammation have been considered to play critical roles in the pathogenesis of colon cancer, the anti-angiogenic and anti-inflammatory effects of vitamin B6 may elucidate the mechanisms underlying the anti-tumor properties of vitamin B6.

Peroxisome proliferator-activated receptor- γ (PPAR γ) is one such protein that may explain, in part, the anti-tumor behavior of vitamin B6. PPAR γ , one of three PPAR subtypes (PPAR α , PPAR γ and PPAR δ/β), is a ligand-dependent transcription factor that belongs to the nuclear hormone receptor superfamily (9). PPAR γ is found highly expressed in adipose tissue, and to a lesser extent in the colon and immune system (10). PPAR γ enhances adipocyte-specific gene expression via the formation of a heterodimeric DNA-binding complex with the retinoid X receptor. To date, overexpression and knockout studies with mice strongly suggest that PPAR γ is an essential transcription factor in adipogenesis *in vitro* and *in vivo* (11,12). Furthermore, the most extensively employed insulin-sensitizing drugs, thiazolidinedione derivatives (TZDs), such as

Correspondence to: Dr Noriyuki Yanaka, Department of Bioresource Science and Technology, Graduate School of Biosphere Science, Hiroshima University, 4-4 Kagamiyama 1-chome, Higashi-Hiroshima 739-8528, Japan
E-mail: yanaka@hiroshima-u.ac.jp

Abbreviations: PPAR γ , peroxisome proliferator-activated receptor- γ ; TZD, thiazolidinedione; PLP, pyridoxal 5'-phosphate; PBS, phosphate-buffered saline

Key words: vitamin B6, 3T3-L1, peroxisome proliferator-activated receptor- γ , adipocytes

troglitazone, pioglitazone and rosiglitazone, have been found to possess a high affinity for PPAR γ (13), suggesting that the pharmacological actions of TZDs are mediated through PPAR γ activation in adipocytes. It has been reported that improvement in insulin resistance by PPAR γ activation is due to an increase in the number of differentiating adipocytes, which promotes adipose-secreted hormone expression and, eventually, glucose homeostasis (9). Furthermore, several substances including the prostaglandin J2 derivative are potent natural ligands of PPAR γ (14) which control a variety of physiological functions through the PPAR γ signaling pathway.

Activation of PPAR γ via TZDs has been found to elicit both anti-neoplastic and anti-inflammatory effects. Therefore, PPAR γ is expected to be a pharmacological target for several types of cancers and cardiovascular diseases (15,16). In colon carcinogenesis, troglitazone, one of the TZDs, has been shown to inhibit tumor growth (17) and to reduce the number of aberrant crypt foci, which are precursor lesions of colon cancer in the colon of mice administered AOM (18,19). In addition, recent reports have demonstrated that the anti-atherosclerotic effect of TZDs is partially explained by the anti-inflammatory functions of PPAR γ , and that TZDs inhibit the expression of various inflammatory proteins including iNOS and COX2 in macrophages. To date, several mechanisms underlying the anti-inflammatory effects of PPAR γ ligands have been proposed, including the inhibition of NF- κ B activity (20).

Kawada *et al* previously tested the effects of vitamins and their analogues on the terminal differentiation of 3T3-L1 cells and found that vitamin B6 derivatives regulated adipogenesis of 3T3-L1 adipocyte cells (21). As the pharmacological properties of TZDs appear to be similar to the biological effects of vitamin B6, we hypothesized that vitamin B6 regulates PPAR γ activation similar to TZDs. To examine this hypothesis, we investigated whether vitamin B6 affects adipogenesis in 3T3-L1 adipocytes, which are able to be efficiently differentiated in the presence of TZDs and support PPAR γ target gene mRNA expression. The present study shows that treatment with PLP, one of the vitamin B6 derivatives, accelerates adipogenesis in 3T3-L1 adipocytes and that PLP up-regulates the expression of PPAR γ target genes in NIH3T3 cells transfected with PPAR γ . Furthermore, an acute administration of vitamin B6 was shown to enhance the expression of a PPAR γ target gene *in vivo*. These observations suggest that vitamin B6 plays an important role as an activator of PPAR γ *in vitro* and *in vivo*.

Materials and methods

Chemical reagents. Pyridoxal hydrochloride, PLP and pyridoxine hydrochloride were obtained from Nacalai Tesque (Osaka, Japan). T-174 [5-[2-(naphthalenylmethyl)-5-benzoxazolyl]-methyl]-2,4-thiazolidinedione, a specific ligand for PPAR γ , was kindly provided by Tanabe Mitsubishi Pharma Co. (Osaka, Japan).

Cell culture. Mouse 3T3-L1 preadipocytes, NIH3T3 cells and Phoenix 293 cells were cultured in a maintenance medium (10% fetal calf serum, 100 U/ml penicillin and 100 μ g/ml streptomycin in Dulbecco's modified Eagle's medium at 37°C in 5% CO₂/95% air under a humidified

condition. High titer retroviruses harboring PPAR γ were produced in Phoenix 293 cells and used to infect NIH3T3 cells, as reported previously (22).

Adipocyte differentiation and Oil-Red-O staining. For differentiation assays, confluent 3T3-L1 cells were treated with differentiation medium [maintenance medium plus 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)], 5 μ g/ml insulin, and 1 μ M dexamethasone (DEX) and incubated for 2 days. Differentiation medium was then replaced with adipocyte growth medium (maintenance medium supplemented with 5 μ g/ml insulin) with or without PLP, which was refreshed every 2 days. Differentiated 3T3-L1 cells were fixed with 4% buffered paraformaldehyde for 15 min. A stock solution of 0.3% Oil-Red-O (Sigma) in isopropanol (w/v) was diluted 6:4 prepared in water, filtered and added to the fixed cells. Cells were washed twice in phosphate-buffered saline (PBS) and photographed.

Glycerol-3-phosphate dehydrogenase activity. Differentiated 3T3-L1 cells were washed twice with ice-cold PBS and suspended in 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin, and 1 mg/ml leupeptin. Membranes were disrupted by sonication, and supernatants were collected following centrifugation at 13,000 \times g for 10 min. The reaction was initiated by the addition of supernatants to a standard mixture containing 100 mM triethanolamine/HCl buffer (pH 7.5), 2.5 mM EDTA, 0.12 mM β -nicotinamide adenine dinucleotide disodium salt (NADH), 0.2 mM dihydroxyacetone-phosphate and 0.1 mM β -mercaptoethanol. The change in absorbance at 340 nm was measured using a spectrophotometer at 25°C. One unit of enzyme activity was determined to correspond to the oxidation of 1 nmol of NADH/min.

Experimental animals. Male ICR mice (5-weeks old) (Charles River Japan Inc., Japan) were housed in groups of 6 animals in plastic cages in a room with controlled temperature (24°C) and a 12-h light/dark cycle. The animals were provided with free access to the diet and water and were maintained according to the 'Guide for the Care and Use of Laboratory Animals' established by Hiroshima University. The experimental diet (vitamin B6-free) consisted of the following components (in g/kg diet): α -corn starch, 402; casein, 200; sucrose, 200; corn oil, 100; cellulose, 50; AIN-93G salt mixture, 35; AIN-93 vitamin mixture (pyridoxine-free), 10; L-cystine, 3. The experimental feeding period was 2 weeks, and the mice were divided into 3 groups of 8 mice each. The animals received an oral administration of pyridoxine hydrochloride (200 or 500 mg/kg body weight) or physiological saline. Six hours after oral administration, epididymal fat pads were removed.

Northern blot hybridization. Total RNA from differentiated 3T3-L1 cells was isolated using Isogen (Nippon Gene). Total RNA from mouse adipose tissues was isolated using RNeasy lipid tissue kit (Qiagen). Total RNA (10 μ g) was subjected to Northern blot hybridization. Briefly, RNA was fractionated in 1% agarose gel containing 0.66 M formaldehyde and 0.02 M MOPS (pH 7.0). Fractionated RNAs were transferred onto a Hybond-N⁺ nylon filter (GE Healthcare) by capillary blotting




Figure 1. The effect of vitamin B6 on adipogenesis in 3T3-L1 adipocytes. (A) 3T3-L1 adipocytes were treated with 100 μ M PLP for 12 days (from day 2-14). Intracellular lipid droplets were visualized by Oil-Red-O staining. (B) GPDH activity was determined after a 12-day cultivation with vitamin B6 at the indicated concentrations. The GPDH activity of untreated cells was set at 100%, and the relative activities were presented as fold induction compared to that of the untreated cells (C). Values are the mean \pm SE (n=5). *P<0.05 vs. control.

and then cross-linked by ultraviolet irradiation. cDNA fragments of mouse adipocyte fatty acid-binding protein (aP2) and mouse glycerol kinase (GyK) were amplified using specific primers. Primers were as follows: aP2 forward primer, 5'-GAAGACAGCTCCTCCTCGAAGGTT-3'; aP2 reverse primer, 5'-GGAAGTCACGCCTTTCATAACA-3'; GyK forward primer, 5'-TGGTGTGTCAGCAACCAGAGGGA-3'; GyK reverse primer, 5'-GGCCATAGATCTCAGAAGAAC-3'. 32 P-labeled cDNA fragments encoding aP2, GyK, human β -actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used for Northern blot hybridization as probes. Hybridization was performed in PerfectHyb (Toyobo) at 65°C for 20 h. The membrane was finally washed with 0.2X SSC and 0.1% SDS at 65°C for 30 min, and the hybridization signals were analyzed using the BAS system (Fuji Film).

Statistical analyses. Values are presented as the means \pm SE. Statistical significance among the means was estimated at P<0.05 according to the Student's t-test.

Results

The effect of vitamin B6 on adipogenesis in 3T3-L1 adipocytes. To investigate the effect of vitamin B6 on adipogenesis,




Figure 2. PLP induces the mRNA expression of PPAR γ target genes in 3T3-L1 adipocytes. On day 6 after induction of differentiation, 3T3-L1 adipocytes were treated with 10 μ M T-174 (T) or 100 μ M PLP for 24 or 48 h. (A) Total RNA (10 μ g) from 3T3-L1 cells was prepared and subjected to Northern blot analyses. (B) The radioactivity in each band was quantified using an image analyzer and normalized to that of β -actin mRNA.

3T3-L1 preadipocytes, which are well characterized as an *in vitro* model of adipocyte differentiation were used. 3T3-L1 cells differentiated into mature adipocytes upon exposure to a hormonal stimulus (0.5 mM IBMX, 5 μ g/ml insulin and 1 μ M DEX). After a 2-day incubation with the hormonal mixture, 3T3-L1 cells were cultured in a medium containing vitamin B6 for 12 days and then subjected to Oil-Red-O staining for lipid droplet visualization. As shown in Fig. 1A, 3T3-L1 cells treated with PLP accumulated larger and a greater number of lipid droplets than the control cells. Since glycerol-3-phosphate dehydrogenase (GPDH) occupies a central position in the pathway of triglyceride synthesis, GPDH enzyme activity was measured as an adipocyte differentiation marker. In agreement with the Oil-Red-O staining, treatment with 100 μ M PLP resulted in a significant increase (by 60%) in GPDH enzyme activity compared to untreated cells (Fig. 1B).

PLP induces the expression of PPAR γ target genes in 3T3-L1 adipocytes. As described above, PLP promoted adipogenesis in 3T3-L1 cells. Subsequently, mRNA expression of PPAR γ target genes was investigated in the differentiated 3T3-L1 adipocytes. On day 6 after differentiation was induced with the hormonal stimulus, 3T3-L1 cells were treated with either a vehicle control (DMSO), 10 μ M T-174 or 100 μ M PLP for 24 or 48 h. After 24 h, the addition of 10 μ M T-174 resulted in an increase in the mRNA expression levels of PPAR γ target genes, aP2 and GyK (Fig. 2). Although the addition of 100 μ M PLP for 24 h had no influence on the mRNA expression levels of PPAR γ target genes, PLP treatment for 48 h demonstrated 1.6- and 4.3-fold increases in the mRNA expression levels of aP2 and GyK genes, respectively (Fig. 2).




Figure 3. PLP enhances lipid accumulation and *aP2* mRNA expression in NIH3T3 cells stably transfected with PPAR γ . Retroviruses harboring PPAR γ were used to infect NIH3T3 cells. (A) NIH3T3 cells stably expressing PPAR γ (NIH3T3/PPAR γ) were treated with 250 μ M PLP for 96 h. Intracellular lipid droplets were visualized by Oil-Red-O staining. (B) NIH3T3/PPAR γ cells were treated with 100 μ M or 250 μ M PLP for 48 or 96 h. Total RNA (10 μ g) from NIH3T3 cells was prepared and subjected to Northern blot analyses.




Figure 4. The effect of the acute administration of vitamin B6 on *aP2* mRNA expression in mouse adipose tissues. (A) Mice were fed a vitamin B6-free diet for 2 weeks and then received an oral administration of pyridoxine hydrochloride (200 or 500 mg/kg body weight) or physiological saline as control. After a 6-h administration of pyridoxine hydrochloride, 10 μ g of total RNA from epididymal fat pads was isolated and subjected to Northern blot analysis. (B) The radioactivity in each band was quantified using an image analyzer and normalized to that of 18S. Each value relative to the mRNA level of the control mice represents the mean \pm SE. (n=4). **P<0.01 vs. control.

PLP induces the expression of a PPAR γ target gene in NIH3T3 cells transfected with PPAR γ . PLP was shown to up-regulate mRNA expression in PPAR γ target genes in differentiated

3T3-L1 adipocytes. To examine whether PLP activates PPAR γ -dependent transcription in cultured cells, retroviruses harboring PPAR γ were used to infect NIH3T3 cells. In PPAR γ -transfected NIH3T3 cells, PLP enhanced *aP2* mRNA expression and lipid accumulation (Fig. 3). Taken together, these results showed that PLP activates PPAR γ -dependent transcription in cultured cells.

The effect of acute administration of vitamin B6 on expression of a PPAR γ target gene in mouse adipose tissues. The present study demonstrated that PLP promotes adipogenesis in 3T3-L1 cells and the mRNA expression of PPAR γ target genes in differentiated 3T3-L1 adipocytes. Therefore, we aimed to ascertain whether vitamin B6 regulates the expression of a PPAR γ target gene *in vivo* and to examine the effect of vitamin B6 on the transactivation activity of PPAR γ *in vivo*. ICR mice were fed a vitamin B6-free diet for 2 weeks, and the animals subsequently received an oral administration of pyridoxine hydrochloride (either 200 or 500 mg/kg body weight). Six hours after oral administration, total RNA was isolated from the epididymal fat pads. The administration of vitamin B6 significantly increased *aP2* mRNA level in the adipose tissues in a dose-dependent manner (Fig. 4).

Discussion

In the present study, PLP, one of the vitamin B6 derivatives, was found to promote adipogenesis in 3T3-L1 cells and up-regulate PPAR γ -dependent gene expression *in vitro* and *in vivo*. To address whether the effect of PLP on adipogenesis is dependent on the transactivation of PPAR γ , NIH3T3 cells stably infected with retroviruses encoding PPAR γ were constructed. NIH3T3 cells, which are not committed to adipocytes, have been well studied and show a similar phenotype to 3T3-L1 cells when PPAR γ is expressed. In fact,

adipocyte differentiation of PPAR γ -infected cells was induced in response to T-174 treatment (data not shown), indicating that NIH3T3 cells stably expressing PPAR γ are well suited for monitoring adipogenesis simply for PPAR γ activation capabilities. In this stable cell line, PLP was shown to promote lipid accumulation, strongly suggesting that PLP stimulates PPAR γ transactivation.

Two molecular mechanisms by which PLP affects the expression of PPAR γ target genes in a direct or indirect manner were considered for study. First, as it was previously reported that thiazolidine compounds are produced by condensation of aminothiols, such as cysteine, with PLP under a physiological condition (23), PLP may act as a PPAR γ ligand by conversion to thiazolidine compounds. Indeed, PLP treatment alone was shown to require more time to induce mRNA expression of PPAR γ target genes compared to T-174 treatment. In general, PPAR γ ligands are well characterized as lipophilic substances, which contain long-chain polyunsaturated fatty acids and fatty acid metabolites, such as 15-deoxy- Δ 12,14-prostaglandin J₂. PPAR γ is thought to have a larger ligand-binding pocket compared to that of other nuclear receptors (24), which may allow PLP-derived compounds to act as ligands. However, observations in this study raise a critical question concerning the selectivity of PLP for PPAR γ target genes. As shown in Fig. 2, PLP was shown to up-regulate *aP2* and *GyK* mRNA expression, but not lipoprotein lipase (LPL) (data not shown), which is also a well-known PPAR γ target gene (25), in 3T3-L1 cells. There is increasing evidence that transcriptional regulation varies even among the PPAR γ -responsive genes via distinct mechanisms (26-28), and, in fact, several isoprenols were found to induce the expression of *aP2* mRNA, but not LPL mRNA in 3T3-L1 cells (29), suggesting that PLP may act as a partial (or weak) agonist similar to the isoprenols.

Second, PLP may influence the interaction of cofactors with PPAR γ , as it has been proposed that ligand-induced transcriptions of PPAR γ target genes are mediated via the recruitment of distinct cofactors (26-28). Recently, Huq *et al* found an important role for vitamin B6 in gene regulation by direct PLP conjugation to receptor interacting protein 140 (RIP140) (30). RIP140 was originally identified as a ligand-dependent co-repressor which binds to estrogen receptors, and, to date, has been shown to interact with and repress a number of other nuclear receptors, including thyroid hormone receptors and estrogen-related receptors (31). Leonardsson *et al* reported that RIP140-null mice show defects in fat accumulation and energy expenditure in adipose tissues, suggesting an important role of RIP140 in regulating the balance between energy storage and energy expenditure (32). Furthermore, in RIP140-null adipocytes, energy expenditure was reportedly elevated with high expression levels of uncoupling protein 1 (*Ucp1*) and carnitine palmitoyltransferase 1b mRNAs (33). Debevec *et al* proposed that the absence of RIP140 leads to the recruitment of PPAR γ , together with PPAR α and estrogen receptor α , to the *UCP1* enhancer to allow activation of *Ucp1* gene transcription (34). These observations prompted us to further consider the physiological significance of the conjugation between PLP and RIP140 for PPAR γ activation in adipocytes.

In summary, these observations presented here show that vitamin B6 up-regulates the expression of PPAR γ target genes *in vitro* and *in vivo*. This study indicates a novel physiological

function of vitamin B6 which may be, in part, mediated by PPAR γ activation. The anti-tumor and anti-inflammatory effects of vitamin B6, furthermore, may relate to PPAR γ activation. Further study is necessary to elucidate the molecular mechanism underlying the action of vitamin B6 on PPAR γ .

Acknowledgements

We are grateful to Drs Yasutomi Kamei and Junko Mizukami for their technical advice. This study was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. Moon WH and Kirksey A: Cellular growth during prenatal and early postnatal periods in progeny of pyridoxine-deficient rats. *J Nutr* 103: 123-133, 1973.
2. Haynes WG: Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. *Cardiovasc Drugs Ther* 16: 391-399, 2002.
3. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P and Mannucci PM: Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. *Circulation* 104: 2442-2446, 2001.
4. Onorato JM, Jenkins AJ, Thorpe SR and Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. *J Biol Chem* 275: 21177-21184, 2000.
5. Komatsu SI, Watanabe H, Oka T, Tsuge H, Nii H and Kato N: Vitamin B-6-supplemented diets compared with a low vitamin B-6 diet suppress azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. *J Nutr* 131: 2204-2207, 2001.
6. Komatsu S, Watanabe H, Oka T, Tsuge H and Kat N: Dietary vitamin B6 suppresses colon tumorigenesis, 8-hydroxyguanosine, 4-hydroxynonenal, and inducible nitric oxide synthase protein in azoxymethane-treated mice. *J Nutr Sci Vitaminol* 48: 65-68, 2002.
7. Matsubara K, Mori M, Matsuura Y and Kato N: Pyridoxal 5'-phosphate and pyridoxal inhibit angiogenesis in serum-free rat aortic ring assay. *Int J Mol Med* 8: 505-508, 2001.
8. Yanaka N, Koyama TA, Komatsu S, Nakamura E, Kanda M and Kato N: Vitamin B6 suppresses NF- κ B activation in LPS-stimulated mouse macrophages. *Int J Mol Med* 16: 1071-1075, 2005.
9. Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. *Nature* 405: 421-424, 2000.
10. Braissant O, Foulle F, Scotto C, Dauca M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α , - β , and - γ in the adult rat. *Endocrinology* 137: 354-366, 1996.
11. Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) γ : adipose-predominant expression and induction early in adipocyte differentiation. *Endocrinology* 135: 798-800, 1994.
12. Tontonoz P, Hu E, Graves RA, Budavari AI and Spiegelman BM: mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. *Genes Dev* 8: 1224-1234, 1994.
13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). *J Biol Chem* 270: 12953-12956, 1995.
14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM and Evans RM: 15-Deoxy- Δ 12, 14-prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR γ . *Cell* 83: 803-812, 1995.
15. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. *Lancet Oncol* 5: 419-429, 2004.
16. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPAR γ . *Nat Med* 4: 1046-1052, 1998.

17. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A and Hosokawa M: Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. *Cancer Res* 61: 2424-2428, 2001.
18. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsushashi N, Kadowaki T, Ochiai M, Sekihara H and Nakagama H: Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. *Gastroenterology* 124: 361-367, 2003.
19. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ and Glass CK: PPAR γ and PPAR δ negatively regulate specific subsets of lipopolysaccharide and IFN- γ target genes in macrophages. *Proc Natl Acad Sci USA* 100: 6712-6717, 2003.
20. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F and Brossart P: PPAR- γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF- κ B pathways. *Blood* 106: 3888-3894, 2005.
21. Kawada T, Aoki N, Kamei Y, Maeshige K, Nishiu S and Sugimoto E: Comparative investigation of vitamins and their analogues on terminal differentiation, from preadipocytes to adipocytes, of 3T3-L1 cells. *Comp Biochem Physiol A* 96: 323-326, 1990.
22. Yanaka N, Nogusa Y, Fujioka Y, Yamashita Y and Kato N: Involvement of membrane protein GDE2 in retinoic acid-induced neurite formation in Neuro2A cells. *FEBS Lett* 581: 712-718, 2007.
23. Terzuoli L, Leoncini R, Pagani R, Guerranti R, Vannoni D, Ponticelli F and Marinello E: Some chemical properties and biological role of thiazolidine compounds. *Life Sci* 63: 1251-1267, 1998.
24. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L and Berkenstam A: Crystal structure of the ligand binding domain of the human nuclear receptor PPAR γ . *J Biol Chem* 273: 31108-31112, 1998.
25. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B and Auwerx J: PPAR α and PPAR γ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. *EMBO J* 15: 5336-5348, 1996.
26. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y and Kato S: Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. *J Biol Chem* 275: 33201-33204, 2000.
27. Robinson CE, Wu X, Nawaz Z, Onate SA and Gimble JM: A corepressor and chicken ovalbumin upstream promoter transcriptional factor proteins modulate peroxisome proliferator-activated receptor- γ /retinoid X receptor α -activated transcription from the murine lipoprotein lipase promoter. *Endocrinology* 140: 1586-1593, 1990.
28. Guan HP, Ishizuka T, Chui PC, Lehrke M and Lazar MA: Corepressors selectively control the transcriptional activity of PPAR γ in adipocytes. *Genes Dev* 19: 453-461, 2005.
29. Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K and Fushiki T: Dual action of isoprenols from herbal medicines on both PPAR γ and PPAR α in 3T3-L1 adipocytes and HepG2 hepatocytes. *FEBS Lett* 514: 315-322, 2002.
30. Huq MD, Tsai NP, Lin YP, Higgins L and Wei LN: Vitamin B6 conjugation to nuclear corepressor RIP140 and its role in gene regulation. *Nat Chem Biol* 3: 161-165, 2007.
31. Fritah A, Christian M and Parker MG: The metabolic coregulator RIP140: an update. *Am J Physiol Endocrinol Metab* 299: E335-E340, 2010.
32. Leonardsson G, Steel JH, Christian M, Pocock V, Milligan S, Bell J, So PW, Medina-Gomez G, Vidal-Puig A, White R and Parker MG: Nuclear receptor corepressor RIP140 regulates fat accumulation. *Proc Natl Acad Sci USA* 101: 8437-8442, 2004.
33. Christian M, Kiskinis E, Debevec D, Leonardsson G, White R and Parker MG: RIP140-targeted repression of gene expression in adipocytes. *Mol Cell Biol* 25: 9383-9391, 2005.
34. Debevec D, Christian M, Morganstein D, Seth A, Herzog B, Parker M and White R: Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogen-related receptor α . *Mol Endocrinol* 21: 1581-1592, 2007.